In Vivo is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Brought to you by

ArQule generates libraries for Pfizer for up to $117mm

Executive Summary

ArQule could receive up to $117mm from Pfizer under terms of a four-and-a-half year deal in which it will use its parallel synthesis combinatorial chemistry technologies to generate compound libraries for its partner. Pfizer gets worldwide exclusive rights to all compounds developed, and pays (uf)$16mm up front for research and development, about $50.5mm total in annual committed license fees, and another $50.5mm in developmental milestones.
Deal Industry
  • Pharmaceuticals
  • Biotechnology
    • Drug Discovery Tools
      • Molecular Diversity
Deal Status
  • Final
Deal Type
  • Alliance
    • Includes Contract
    • Includes Equity
    • R&D and Marketing (Licensing)

Related Companies